<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7551931\results\search\disease\results.xml">
  <result pre="Zika virus (ZIKV) is an emerging mosquito-borne pathogen associated with" exact="microcephaly" post="and other congenital abnormalities in newborns as well as"/>
  <result pre="is an emerging mosquito-borne pathogen associated with microcephaly and other" exact="congenital" post="abnormalities in newborns as well as neurologic complications in"/>
  <result pre="the Flaviviridae family, which encompasses viruses such as dengue virus," exact="yellow fever" post="virus, West Nile virus, tick-borne encephalitis virus, and Japanese"/>
  <result pre="such as dengue virus, yellow fever virus, West Nile virus," exact="tick-borne encephalitis" post="virus, and Japanese encephalitis virus [1]. The ZIKV is"/>
  <result pre="as dengue virus, yellow fever virus, West Nile virus, tick-borne" exact="encephalitis" post="virus, and Japanese encephalitis virus [1]. The ZIKV is"/>
  <result pre="yellow fever virus, West Nile virus, tick-borne encephalitis virus, and" exact="Japanese encephalitis" post="virus [1]. The ZIKV is a mosquito-borne arbovirus, for"/>
  <result pre="fever virus, West Nile virus, tick-borne encephalitis virus, and Japanese" exact="encephalitis" post="virus [1]. The ZIKV is a mosquito-borne arbovirus, for"/>
  <result pre="its geographic range which consequently brings the threat of arboviral" exact="infections" post="also to the temperate zones [2]. Until now, ZIKV"/>
  <result pre="infections also to the temperate zones [2]. Until now, ZIKV" exact="infections" post="have been confirmed in 91 countries in South and"/>
  <result pre="infections have been confirmed in 91 countries in South and" exact="Central" post="America, Central Africa, South Asia, the South Pacific region,"/>
  <result pre="been confirmed in 91 countries in South and Central America," exact="Central" post="Africa, South Asia, the South Pacific region, and Europe"/>
  <result pre="South Asia, the South Pacific region, and Europe [3,4]. The" exact="infection" post="is frequently asymptomatic (80% of cases), and the disease"/>
  <result pre="The infection is frequently asymptomatic (80% of cases), and the" exact="disease" post="associated with the virus is mild-to-moderate [5]. In symptomatic"/>
  <result pre="the disease associated with the virus is mild-to-moderate [5]. In" exact="symptomatic" post="patients, it manifests itself with flu-like symptoms and in"/>
  <result pre="associated with rash and itching [6]. For that reason, the" exact="disease" post="was neglected for years, and it was not considered"/>
  <result pre="infected with ZIKV during the first trimester of pregnancy, as" exact="congenital" post="malformations of the fetus occur in about 11% of"/>
  <result pre="with ZIKV during the first trimester of pregnancy, as congenital" exact="malformations" post="of the fetus occur in about 11% of cases"/>
  <result pre="in about 11% of cases [7,8]. The symptoms include increased" exact="muscle" post="tone, hyperreflexia, spasticity, paroxysmal cramps, brain calcification, brain atrophy,"/>
  <result pre="The symptoms include increased muscle tone, hyperreflexia, spasticity, paroxysmal cramps," exact="brain" post="calcification, brain atrophy, and enlarged brain chambers [9]. No"/>
  <result pre="include increased muscle tone, hyperreflexia, spasticity, paroxysmal cramps, brain calcification," exact="brain" post="atrophy, and enlarged brain chambers [9]. No defects have"/>
  <result pre="hyperreflexia, spasticity, paroxysmal cramps, brain calcification, brain atrophy, and enlarged" exact="brain" post="chambers [9]. No defects have been observed in neonates"/>
  <result pre="pregnancy [10]. Less severe, but also notable consequences of the" exact="infection" post="were observed in adults and included Guillainâ€&quot;BarrÃ© syndrome and"/>
  <result pre="of the infection were observed in adults and included Guillainâ€&quot;BarrÃ©" exact="syndrome" post="and other neurological disorders. Up to four weeks after"/>
  <result pre="the infection, neurological symptoms may occur in the form of" exact="acute" post="inflammatory demyelinating polyneuropathy, and approximately 50% of patients with"/>
  <result pre="neurological symptoms may occur in the form of acute inflammatory" exact="demyelinating" post="polyneuropathy, and approximately 50% of patients with neurologic sequelae"/>
  <result pre="polyneuropathy, and approximately 50% of patients with neurologic sequelae experience" exact="bilateral" post="facial palsy [11,12]. The pathomechanism leading to this syndrome"/>
  <result pre="experience bilateral facial palsy [11,12]. The pathomechanism leading to this" exact="syndrome" post="is not yet fully understood. It is suspected that"/>
  <result pre="be related to the direct effect of the virus on" exact="nerve" post="cells or excessive immune response to infection. Until now,"/>
  <result pre="as influenza A and B virus [14,15], herpesviruses [16,17,18,19,20,21,22,23,24,25], human" exact="immunodeficiency" post="virus (HIV) [23,26,27], human metapneumovirus (hMPV) [28], and other"/>
  <result pre="highly sulfated heparin, dextran sulfate, and suramin significantly inhibit ZIKV" exact="infection" post="in Vero cells [35]. The current work aimed to"/>
  <result pre="(Human Glioblastoma), Vero (Cercopithecus aethiops kidney epithelial, ATCC CCL-81), and" exact="primary" post="human skin fibroblast (HSF) cells were maintained under Dulbecco-modified"/>
  <result pre="Zika virus strains, H/PF/2013, MR-776, PRAVABC59, Human/2015/Honduras and Mosquito/1966/Malaysia, were" exact="acquired" post="from BEI Resources (Manassas, VA, USA). Stocks of ZIKV"/>
  <result pre="cells) Ã— 100%. 2.4. RNA Isolation and RT-qPCR Isolation of" exact="viral" post="RNA was carried out using a commercially available RNA"/>
  <result pre="Biotechnology, Poland) according to the protocol provided by the manufacturer." exact="Isolated" post="RNA was subjected to reverse transcription (RT) and quantitative"/>
  <result pre="RT-qPCR reaction was carried out using 3 Î¼L of isolated" exact="viral" post="RNA, which was reverse transcribed and amplified in a"/>
  <result pre="Â°C. Appropriate standards were prepared to evaluate the number of" exact="viral" post="RNA molecules in the sample. 2.5. Mechanism of Action"/>
  <result pre="100 ÂµL ZIKV (TCID50 = 400/mL). After four days of" exact="infection" post="at 37 Â°C, supernatants were collected, and the number"/>
  <result pre="(Life technologies, Eugene, OR, USA) and sealed. Fluorescent images were" exact="acquired" post="using Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy"/>
  <result pre="1.52b) Fiji software (Madison, WI, USA) [38]. The number of" exact="viral" post="particles and the number of cells was calculated using"/>
  <result pre="were placed in 12-well plates, overlaid with 40 Î¼g/mL bovine" exact="type I" post="collagen (PureCol, Advanced BioMatrix, US) in PBS and incubated"/>
  <result pre="plates, overlaid with 40 Î¼g/mL bovine type I collagen (PureCol," exact="Advanced" post="BioMatrix, US) in PBS and incubated overnight at 37"/>
  <result pre="in confocal microscopy section. The number of virions for each" exact="focal" post="plane was assessed using the ImageJ Fiji software (National"/>
  <result pre="Results 3.1. PSSNa Shows No Toxicity Towards Somatic, Glioblastoma and" exact="Primary" post="Cells XTT assay was carried out to assess the"/>
  <result pre="of high MW (Figure 1 and Figure S1A). For the" exact="intermediate" post="dose of 1 mg/mL the cytotoxicity could not be"/>
  <result pre="kDa were amongst the most toxic ones. For PSSNa of" exact="lower" post="MW we did not observe any marked cytotoxicity at"/>
  <result pre="U251 cells was infected with ZIKV in the presence or" exact="absence of" post="each of 19 tested PSSNa polymers of different MW."/>
  <result pre="results indicate that in many cases PSSNa at this concentration" exact="limited" post="ZIKV replication below the RT-qPCR detection threshold (1000 RNA"/>
  <result pre="more substantial inhibitory effect (&amp;gt;4 logs inhibition), while polymers of" exact="lower" post="MW showed weaker inhibition (2â€&quot;4 logs inhibition). However, this"/>
  <result pre="inhibition). However, this correlation had to be tested later using" exact="lower" post="PSSNa concentrations. Therefore, for further studies, four polymers with"/>
  <result pre="respectively. In Vero cells, all tested PSSNa polymers hampered ZIKV" exact="infection" post="in a dose-dependent manner. Low cytotoxicity and strong inhibition"/>
  <result pre="and are listed in Table 1. Moreover, in HSF cells," exact="complete" post="inhibition (below RT-qPCR detection limit) of ZIKV replication was"/>
  <result pre="were infected with four ZIKV strains of both Asian and" exact="African" post="lineage and isolated from different host species (MR 766"/>
  <result pre="limit of RT-qPCR (Figure 4). PSSNa hampers the replication of" exact="African" post="lineage strain MR766. The molecular weight correlated with the"/>
  <result pre="where the polymer is present during the early stages of" exact="viral infection," post="but the effect was non-significant or mild (Assays II"/>
  <result pre="(Assays II and III). While one cannot exclude an additional" exact="secondary" post="mechanism of action, we believe that the observed effect"/>
  <result pre="temperature blocking the virus internalization, PSSNa decreases the number of" exact="viral" post="particles attached to the cell (Figure 7). Thus, the"/>
  <result pre="negatively charged polymer, poly(sodium 4-styrenesulfonate) (PSSNa) can efficiently hamper ZIKV" exact="infection" post="in vitro by directly binding to the virus and"/>
  <result pre="the virus to the host cell. PSSNa vastly decreases the" exact="viral" post="replication in vitro in a number of cellular models,"/>
  <result pre="if PSSNa can permanently inactivate ZIKV virions or produce a" exact="stable" post="virusâ€&quot;PSSNa complex. Therefore, another possibility is to utilize PSSNa"/>
  <result pre="inhibitory doses. Analysis of the potential binding sites on the" exact="viral" post="particle suggests that PSSNa may bind with the fusion"/>
  <result pre="of high molecular weight PSSNa compared to the ones with" exact="lower" post="MW was observed. One may speculate that such an"/>
  <result pre="Zika Virus Life Cycle: What to Expect from Megadiverse Latin" exact="American" post="CountriesPLoS Negl. Trop. Dis.201610e000507310.1371/journal.pntd.000507328005902 3.collab: World Health OrganisationCountries and"/>
  <result pre="and infants of US women with evidence of possible zika" exact="virus infection" post="during pregnancyJAMA J. Am. Med. Assoc.2017317596810.1001/jama.2016.1900627960197 8.RobinsonC.L.ChongA.C.N.AshbrookA.W.JengG.JinJ.ChenH.TangE.I.MartinL.A.KimR.S.KenyonR.M.et al.Male germ"/>
  <result pre="infants of US women with evidence of possible zika virus" exact="infection" post="during pregnancyJAMA J. Am. Med. Assoc.2017317596810.1001/jama.2016.1900627960197 8.RobinsonC.L.ChongA.C.N.AshbrookA.W.JengG.JinJ.ChenH.TangE.I.MartinL.A.KimR.S.KenyonR.M.et al.Male germ"/>
  <result pre="9.AdachiK.Nielsen-SainesK.Zika clinical updates: Implications for pediatricsCurr. Opin. Pediatr.20183010511610.1097/MOP.000000000000058229176498 10.BrasilP.PereiraJ.P.MoreiraM.E.NogueiraR.M.R.DamascenoL.WakimotoM.RabelloR.S.ValderramosS.G.HalaiU.A.SallesT.S.et al.Zika" exact="virus infection" post="in pregnant women in rio de janeiroN. Engl. J."/>
  <result pre="clinical updates: Implications for pediatricsCurr. Opin. Pediatr.20183010511610.1097/MOP.000000000000058229176498 10.BrasilP.PereiraJ.P.MoreiraM.E.NogueiraR.M.R.DamascenoL.WakimotoM.RabelloR.S.ValderramosS.G.HalaiU.A.SallesT.S.et al.Zika virus" exact="infection" post="in pregnant women in rio de janeiroN. Engl. J."/>
  <result pre="rio de janeiroN. Engl. J. Med.20163752321233410.1056/NEJMoa160241226943629 11.BarbiL.CoelhoA.V.C.de AlencarL.C.A.CrovellaS.Prevalence of Guillain-BarrÃ©" exact="syndrome" post="among Zika virus infected cases: A systematic review and"/>
  <result pre="A systematic review and meta-analysisBraz. J. Infect. Dis.20182213714110.1016/j.bjid.2018.02.00529545017 12.ParraB.LizarazoJ.JimÃ©nez-ArangoJ.A.Zea-VeraA.F.GonzÃ¡lez-ManriqueG.VargasJ.AngaritaJ.A.ZuÃ±igaG.Lopez-GonzalezR.BeltranC.L.et al.Guillain-BarrÃ©" exact="syndrome" post="associated with Zika virus infection in ColombiaN. Engl. J."/>
  <result pre="meta-analysisBraz. J. Infect. Dis.20182213714110.1016/j.bjid.2018.02.00529545017 12.ParraB.LizarazoJ.JimÃ©nez-ArangoJ.A.Zea-VeraA.F.GonzÃ¡lez-ManriqueG.VargasJ.AngaritaJ.A.ZuÃ±igaG.Lopez-GonzalezR.BeltranC.L.et al.Guillain-BarrÃ© syndrome associated with Zika" exact="virus infection" post="in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 13.RandazzoW.FabraM.J.FalcÃ³I.LÃ³pez-RubioA.SÃ¡nchezG.Polymers and Biopolymers with"/>
  <result pre="J. Infect. Dis.20182213714110.1016/j.bjid.2018.02.00529545017 12.ParraB.LizarazoJ.JimÃ©nez-ArangoJ.A.Zea-VeraA.F.GonzÃ¡lez-ManriqueG.VargasJ.AngaritaJ.A.ZuÃ±igaG.Lopez-GonzalezR.BeltranC.L.et al.Guillain-BarrÃ© syndrome associated with Zika virus" exact="infection" post="in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 13.RandazzoW.FabraM.J.FalcÃ³I.LÃ³pez-RubioA.SÃ¡nchezG.Polymers and Biopolymers with"/>
  <result pre="Correlation as Inhibitors of Influenza InfectivityMol. Pharm.20171423424110.1021/acs.molpharmaceut.6b0082628043136 16.CarlucciM.J.ScolaroL.A.DamonteE.B.Herpes simplex virus" exact="type 1" post="variants arising after selection with an antiviral carrageenan: Lack"/>
  <result pre="BoHV-1 and SuHV-1Res. Vet. Sci.20159814214410.1016/j.rvsc.2014.11.01025435342 18.NahmiasA.J.KibrickS.Inhibitory effect of heparin on" exact="herpes" post="simplex virusJ. Bacteriol.1964871060106610.1128/JB.87.5.1060-1066.19644289440 19.PachotaM.KlysikK.SynowiecA.CiejkaJ.SzczubiaÅ‚kaK.PyrÄ‡K.NowakowskaM.Inhibition of Herpes Simplex Viruses by"/>
  <result pre="dendrimers: SPL-2999 inhibits both virus entry and late stages of" exact="herpes" post="simplex virus replicationAntivir. Res.20025531932910.1016/S0166-3542(02)00054-212103432 21.HeroldB.C.BourneN.MarcellinoD.KirkpatrickR.StraussD.M.ZaneveldL.J.D.WallerD.P.AndersonR.A.ChanyC.J.BarhamB.J.et al.Poly(sodium 4-styrene sulfonate): An"/>
  <result pre="functional microbicideAntivir. Res.20129613814710.1016/j.antiviral.2012.08.00522940611 24.CarlucciM.J.ScolaroL.A.NosedaM.D.CerezoA.S.DamonteE.B.Protective effect of a natural carrageenan on" exact="genital herpes" post="simplex virus infection in miceAntivir. Res20046413714110.1016/j.antiviral.2004.07.00115498610 25.PachotaM.KÅ‚ysik-TrzciaÅ&quot;skaK.SynowiecA.YukiokaS.YusaS.I.ZajacM.ZawilinskaB.DzieciatkowskiT.SzczubialkaK.PyrcK.et al.Highly Effective"/>
  <result pre="microbicideAntivir. Res.20129613814710.1016/j.antiviral.2012.08.00522940611 24.CarlucciM.J.ScolaroL.A.NosedaM.D.CerezoA.S.DamonteE.B.Protective effect of a natural carrageenan on genital" exact="herpes" post="simplex virus infection in miceAntivir. Res20046413714110.1016/j.antiviral.2004.07.00115498610 25.PachotaM.KÅ‚ysik-TrzciaÅ&quot;skaK.SynowiecA.YukiokaS.YusaS.I.ZajacM.ZawilinskaB.DzieciatkowskiT.SzczubialkaK.PyrcK.et al.Highly Effective"/>
  <result pre="24.CarlucciM.J.ScolaroL.A.NosedaM.D.CerezoA.S.DamonteE.B.Protective effect of a natural carrageenan on genital herpes simplex" exact="virus infection" post="in miceAntivir. Res20046413714110.1016/j.antiviral.2004.07.00115498610 25.PachotaM.KÅ‚ysik-TrzciaÅ&quot;skaK.SynowiecA.YukiokaS.YusaS.I.ZajacM.ZawilinskaB.DzieciatkowskiT.SzczubialkaK.PyrcK.et al.Highly Effective and Safe Polymeric"/>
  <result pre="effect of a natural carrageenan on genital herpes simplex virus" exact="infection" post="in miceAntivir. Res20046413714110.1016/j.antiviral.2004.07.00115498610 25.PachotaM.KÅ‚ysik-TrzciaÅ&quot;skaK.SynowiecA.YukiokaS.YusaS.I.ZajacM.ZawilinskaB.DzieciatkowskiT.SzczubialkaK.PyrcK.et al.Highly Effective and Safe Polymeric"/>
  <result pre="in VivoACS Appl. Mater. Interfaces201911267452675210.1021/acsami.9b1030231287654 26.LeydetA.BarraganV.BoyerB.MontÃ©roJ.L.RoqueJ.P.WitvrouwM.EsteJ.SnoeckR.AndreiG.De ClercqE.Polyanion inhibitors of human" exact="immunodeficiency" post="virus and other viruses. 5. Telomerized anionic surfactants derived"/>
  <result pre="as inhibitors of human metapneumovirusPLoS ONE201914e021464610.1371/journal.pone.021464630921418 29.TalaricoL.B.NosedaM.D.DucattiD.R.B.DuarteM.E.R.DamonteE.B.Differential inhibition of dengue" exact="virus infection" post="in mammalian and mosquito cells by iota-carrageenanJ. Gen. Virol.2011921332134210.1099/vir.0.028522-021325483"/>
  <result pre="inhibitors of human metapneumovirusPLoS ONE201914e021464610.1371/journal.pone.021464630921418 29.TalaricoL.B.NosedaM.D.DucattiD.R.B.DuarteM.E.R.DamonteE.B.Differential inhibition of dengue virus" exact="infection" post="in mammalian and mosquito cells by iota-carrageenanJ. Gen. Virol.2011921332134210.1099/vir.0.028522-021325483"/>
  <result pre="the composition of the target amino acid sequences of the" exact="viral" post="envelope glycoproteinsAntimicrob. Agents Chemother.1991352515252010.1128/AAC.35.12.25151725692 35.TanC.W.SamI.C.ChongW.L.LeeV.S.ChanY.F.Polysulfonate suramin inhibits Zika virus"/>
  <result pre="Whiteâ€™s Med. Virol.2017493518 41.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ZhangY.YuanY.SongH.HaywoodJ.et al.Structures of the Zika Virus Envelope" exact="Protein" post="and Its Complex with a Flavivirus Broadly Protective AntibodyCell"/>
  <result pre="41.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ZhangY.YuanY.SongH.HaywoodJ.et al.Structures of the Zika Virus Envelope Protein and Its" exact="Complex" post="with a Flavivirus Broadly Protective AntibodyCell Host Microbe20161969670410.1016/j.chom.2016.04.01327158114 42.MilewskaA.KaminskiK.CiejkaJ.KosowiczK.ZeglenS.WojarskiJ.NowakowskaM.SzczubiaÅ‚kaK.PyrcK.HTCC:"/>
  <result pre="polymers at the concentration of 0.5 mg/mL. Inhibition of the" exact="infection" post="was evaluated using RT-qPCR. Data are shown as virus"/>
  <result pre="using RT-qPCR. Data are shown as virus yield (copies of" exact="viral" post="genome per milliliter). All experiments were performed in triplicate."/>
  <result pre="cycle by PSSNa in different cell types. Inhibition of the" exact="infection" post="was evaluated using RT-qPCR. U251 (A) and Vero (B)"/>
  <result pre="presence of different polymers for four days. Inhibition of the" exact="infection" post="was evaluated using RT-qPCR. Data are shown as virus"/>
  <result pre="using RT-qPCR. Data are shown as virus yield (copies of" exact="viral" post="genome per milliliter). The results are presented as average"/>
  <result pre="of PSSNa of different MW at different stages of ZIKV" exact="infection" post="cycle. Functional Assays Iâ€&quot;IV were carried out on U251"/>
  <result pre="and egress assay (Assay IV, (D)). The inhibition of the" exact="infection" post="was evaluated using RT-qPCR. All experiments were performed in"/>
  <result pre="as a positive control. Results show RT-qPCR analyses (copies of" exact="viral" post="genome per milliliter). The results are presented as average"/>
 </snippets>
</snippetsTree>
